GB2025938A - Pt(II)-amine Complexes - Google Patents
Pt(II)-amine Complexes Download PDFInfo
- Publication number
- GB2025938A GB2025938A GB7841111A GB7841111A GB2025938A GB 2025938 A GB2025938 A GB 2025938A GB 7841111 A GB7841111 A GB 7841111A GB 7841111 A GB7841111 A GB 7841111A GB 2025938 A GB2025938 A GB 2025938A
- Authority
- GB
- United Kingdom
- Prior art keywords
- composition according
- group
- platinum
- cis
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims abstract description 73
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 39
- 229910001868 water Inorganic materials 0.000 claims abstract description 39
- 229910052697 platinum Inorganic materials 0.000 claims abstract description 24
- 150000001875 compounds Chemical class 0.000 claims abstract description 19
- 239000003446 ligand Substances 0.000 claims abstract description 12
- 150000007942 carboxylates Chemical class 0.000 claims abstract description 11
- 229910021653 sulphate ion Inorganic materials 0.000 claims abstract description 6
- 229910019142 PO4 Inorganic materials 0.000 claims abstract description 5
- 150000001412 amines Chemical class 0.000 claims abstract description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims abstract description 5
- 239000010452 phosphate Substances 0.000 claims abstract description 5
- 229910002651 NO3 Inorganic materials 0.000 claims abstract description 3
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims abstract description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract description 3
- 239000000203 mixture Substances 0.000 claims description 26
- 229910052739 hydrogen Inorganic materials 0.000 claims description 15
- 239000001257 hydrogen Substances 0.000 claims description 15
- -1 halide sulphate Chemical class 0.000 claims description 12
- 125000003118 aryl group Chemical group 0.000 claims description 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 10
- BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical class OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 claims description 10
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 8
- 125000003342 alkenyl group Chemical group 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 8
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 239000001301 oxygen Substances 0.000 claims description 8
- 125000002577 pseudohalo group Chemical group 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 7
- 150000002367 halogens Chemical class 0.000 claims description 7
- 125000004104 aryloxy group Chemical group 0.000 claims description 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 6
- 150000002431 hydrogen Chemical class 0.000 claims description 5
- 239000005864 Sulphur Substances 0.000 claims description 4
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 4
- 125000003368 amide group Chemical group 0.000 claims description 4
- 150000001734 carboxylic acid salts Chemical class 0.000 claims description 4
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 4
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- HRGDZIGMBDGFTC-UHFFFAOYSA-N platinum(2+) Chemical compound [Pt+2] HRGDZIGMBDGFTC-UHFFFAOYSA-N 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 2
- ASVKKRLMJCWVQF-UHFFFAOYSA-N 3-buten-1-amine Chemical compound NCCC=C ASVKKRLMJCWVQF-UHFFFAOYSA-N 0.000 claims description 2
- 125000004442 acylamino group Chemical group 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 150000001733 carboxylic acid esters Chemical class 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000001624 naphthyl group Chemical class 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- JFIOVJDNOJYLKP-UHFFFAOYSA-N bithionol Chemical compound OC1=C(Cl)C=C(Cl)C=C1SC1=CC(Cl)=CC(Cl)=C1O JFIOVJDNOJYLKP-UHFFFAOYSA-N 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 150000001735 carboxylic acids Chemical class 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 12
- 201000011510 cancer Diseases 0.000 abstract description 8
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 abstract description 5
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 3
- 150000004820 halides Chemical class 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 41
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 32
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 25
- 239000007787 solid Substances 0.000 description 16
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 12
- 239000003610 charcoal Substances 0.000 description 11
- 230000009102 absorption Effects 0.000 description 10
- 238000010521 absorption reaction Methods 0.000 description 10
- DPBLXKKOBLCELK-UHFFFAOYSA-N pentan-1-amine Chemical compound CCCCCN DPBLXKKOBLCELK-UHFFFAOYSA-N 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000013078 crystal Substances 0.000 description 9
- 238000002329 infrared spectrum Methods 0.000 description 9
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 239000012043 crude product Substances 0.000 description 8
- 238000000921 elemental analysis Methods 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 238000009835 boiling Methods 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 235000011149 sulphuric acid Nutrition 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 239000001117 sulphuric acid Substances 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- IRXRGVFLQOSHOH-UHFFFAOYSA-L dipotassium;oxalate Chemical compound [K+].[K+].[O-]C(=O)C([O-])=O IRXRGVFLQOSHOH-UHFFFAOYSA-L 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 3
- 229940106681 chloroacetic acid Drugs 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- CLSUSRZJUQMOHH-UHFFFAOYSA-L platinum dichloride Chemical compound Cl[Pt]Cl CLSUSRZJUQMOHH-UHFFFAOYSA-L 0.000 description 3
- KPFSGNRRZMYZPH-UHFFFAOYSA-M potassium;2-chloroacetate Chemical compound [K+].[O-]C(=O)CCl KPFSGNRRZMYZPH-UHFFFAOYSA-M 0.000 description 3
- 229910001961 silver nitrate Inorganic materials 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229940089960 chloroacetate Drugs 0.000 description 2
- FOCAUTSVDIKZOP-UHFFFAOYSA-M chloroacetate Chemical compound [O-]C(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-M 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 150000004682 monohydrates Chemical class 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- BMVXCPBXGZKUPN-UHFFFAOYSA-N 1-hexanamine Chemical compound CCCCCCN BMVXCPBXGZKUPN-UHFFFAOYSA-N 0.000 description 1
- KDSNLYIMUZNERS-UHFFFAOYSA-N 2-methylpropanamine Chemical compound CC(C)CN KDSNLYIMUZNERS-UHFFFAOYSA-N 0.000 description 1
- 241000220438 Arachis Species 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- KUXVLJIMBMQTPN-UHFFFAOYSA-N ClC(CCCNCCCC)Cl Chemical compound ClC(CCCNCCCC)Cl KUXVLJIMBMQTPN-UHFFFAOYSA-N 0.000 description 1
- DCZQNGLESDNACE-UHFFFAOYSA-N ClC(CCNCCC)Cl Chemical compound ClC(CCNCCC)Cl DCZQNGLESDNACE-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- WJYIASZWHGOTOU-UHFFFAOYSA-N Heptylamine Chemical compound CCCCCCCN WJYIASZWHGOTOU-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 229910021607 Silver chloride Inorganic materials 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- KDPAWGWELVVRCH-UHFFFAOYSA-M bromoacetate Chemical compound [O-]C(=O)CBr KDPAWGWELVVRCH-UHFFFAOYSA-M 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- XLJMAIOERFSOGZ-UHFFFAOYSA-M cyanate Chemical compound [O-]C#N XLJMAIOERFSOGZ-UHFFFAOYSA-M 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N monoethyl amine Natural products CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- IOQPZZOEVPZRBK-UHFFFAOYSA-N octan-1-amine Chemical compound CCCCCCCCN IOQPZZOEVPZRBK-UHFFFAOYSA-N 0.000 description 1
- WLJVNTCWHIRURA-UHFFFAOYSA-M pimelate(1-) Chemical compound OC(=O)CCCCCC([O-])=O WLJVNTCWHIRURA-UHFFFAOYSA-M 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 102220042174 rs141655687 Human genes 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- VSRBKQFNFZQRBM-UHFFFAOYSA-N tuaminoheptane Chemical compound CCCCCC(C)N VSRBKQFNFZQRBM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0086—Platinum compounds
- C07F15/0093—Platinum compounds without a metal-carbon linkage
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A cis co-ordination compound of platinum having the structure <IMAGE> in which X and Y are the same or different ligands selected from halide, sulphate, phosphate, nitrate, carboxylate, and water or together represent decarboxylate and A and B are the same or different straight- chain amines co-ordinated to the Pt through their N atoms, such that the platinum is present as Pt<2+>. These platinum co-ordination compounds and pharmaceutical compositions containing them are useful in the treatment of malignant tumours or malignant neoplasms.
Description
SPECIFICATION
Compositions Containing Platinum
This invention relates to new platinum co-ordination compounds, to pharmaceutical compositions containing them and to their use in the treatment of malignant tumours or malignant neoplasms.
According to a first aspect of the present invention, a composition of matter comprises a cis coordination compound of platinum having the structure
in which X and Y are the same or different ligands selected from halide, sulphate, phosphate, nitrate, carboxylate, substituted carboxylate and water and A and B are the same or different straight-chain amines coordinated to the Pt through their N atoms, such that the platinum is present as Pt2. By phosphate we mean both H2PO4- and HP042-.
Where X and/or Y is represented by carboxylate or substituted carboxylate having the general formula CnR2n+lCO2H where n is an integer from 1 to 9 inclusive and that the B groups are the same or different and are selected from hydrogen, substituted or unsubstituted straight- or branched-chain alkyl, aryl, alkaryl, aralkyl, alkenyl, cycloalkyl and cycloalkenyl, halogen, pseudohalogen, hydroxy, carbonyl, formyl, nitro, amido, amino, alkoxy, aryloxy and sulphonic acid salts. We intend the above definition also to include oxygen and sulphur, such that one doubly-bonded oxygen or sulphur atom is represented by two R groups.
Where X and Y are both carboxylate, then can together comprise a discarboxylate bidentate ligand, for example oxalate and ligands having the general formula -OOC ~(CsIRz2) l-CN- where nl is an integer from 2 to 6, R' and R2 are the same or different and are selected from H, lower alkyl, aryl, alkaryl, aralkyl, alkenyl, cycloalkyl, cycloalkenyl, alkoxy, aryloxy, halogen, pseudohalogen,
OH, or are combined with the carbon atoms to from a cycloalkyl or an aryl group, and substituted derivatives thereof, and y and z are either 0 or 1 as long as (y+z) is equal to 1 or 2.
Suitable dicarboxylate ligands are the succinato, glutarato (pentanedioato), adipato (hexanedioato), pimelato (heptanedioate) malaro (cis-butenedioato) and phthalato (obenzenedicarboxylate) ligands and these may be either substituted or unsubstituted.
The ligands may contain substituents selected from the group consisting of lower alkyl, (e.g.
methyl, ethyl, n-propyl, isopropyl, n-butyl); aryl (e.g. phenyl, lower alkyl-, lower alkenyl-, halo-, nitro-, lower alkoxy-substituted phenyl and naphthyl) aralkyl, (e.g. phenymethyl(benzyl), 2-( 1 -naphthyl) methyl); alkenyl, (e.g. 4-amino-1-butene, allyl); cyclo-alkyl, (e.g. cyclopropyl, cyclohexyl); cyclo-alkenyl, (e.g. 2-cyclopenten-1-yl), 2-cyclo-hexen-1-yl); alkoxy; (e.g. methoxy, ethoxy), and hydroxy.
The straight chain amine has the general formula: n-CXi2x +1i2' in which x is an integer from 1 to 9 inclusive and the R3 groups are the same or different and are selected from hydrogen, aryl, cycloalkyl and cycloalkenyl, aralkyl, halogen, pseudohalogen (as hereinafter defined), hydroxy, alkoxy, aryloxy, carbonyl, formyl, nitro, amido, amino, acylamino, sulphonic acid, sulphonic acid salt, carboxylic acid ester and carboxylic acid salt. Even more preferably
all the R3 groups are hydrogen. However, where one or more of the R3 groups is other than hydrogen, it
can be a solubilising group, for example a sulphonic acid, carboxylic acid, carboxylic acid salt or a sulphonic acid salt.Where a solubilising group is used in the form of a salt, the salt can be, for example, the sodium, potassium or lithium salt, where conditions are appropriate and the clinical conditions require high solubility. We intend the above definition of R3 also to include oxygen and sulphur, such that one doubly-bonded oxygen or sulphur atom is represented by two R3 groups.
The term "pseudohalogen" in this specification has the meaning given on p. 560 of "Advanced
Inorganic Chemistry" by Cotton and Wilkinson, Interscience Publishers, 1966, as being "a molecule consisting of more than two electronegative atoms which in the free state, resembles the halogens; these pseudohalogens give rise to anions which resemble the halide ions in behaviour". Examples of suitable pseudohalogenides are cyanide, cyanate, thiocyanate and azide.
The term "cis" as applied to the compounds of the invention indicates that the compounds have planar structure and that A cannot be in a position trans to B and that X cannot be in a position trans to
Y.
Two particular compounds according to the invention are cis dichloro di-n-propylamine Pt (II) and cis dichloro-di-n-butylamine Pt(ll).
We have found that compounds of the present invention are active against cancers, or malignant tumours or malignant neoplasms. Normally the compound is used in association with a pharmaceutically acceptable carrier therefore. Accordingly, in a second aspect, the present invention provides a pharmaceutical composition which comprises a compound according to the first aspect of the invention and a pharmaceutically-acceptable carrier for said compound; these compositions can be formulated so as to be suitable, for example, for parenteral or oral administration to animals affected with a malignant tumour or neoplasm.
Preparation of Complexes According to the Invention
The following Examples describe some specific preparations of compounds according to the invention.
Examples 1,2 and 3 describe the preparation of compounds formed by reaction of
cis-[Ptl2A2] with AgNO3 and throughout the remainder of this specification such compounds will be referred to as "diaquo compounds" In each case, the cis'[Ptl2A2] may be prepared by the method of S. C. Dhara described in the Indian Journal of Chemistry, 8, 143(1970).
Example 1:
Preparation of the n-Butylamine Diaquo Complex -[ti2 (n-c4H9NH2)zJ (120 g, 0.20 mol) was slurried with a warm solution of silver nitrate (66 g, 0.38 mol) in water (200 ml).
The mixture was stirred for 3 hours during which time the yellow suspension turned pale grey. The mixture was then treated with charcoal, stirred and filtered through a porosity 4 sinter. The residue was washed once with 30 ml of water and the washings were combined with the filtrate (total volume 300 ml). The addition of a crystal of sodium chloride gave no precipitate of AgCI which indicated that the solution was silver free. The solution was treated with charcoal and filtered through a porosity 4 sinter immediately before use since there was a tendency for the pale yellow solution to darken owing to slow decomposition to platinum.
Example 2:
Preparation of the n-Propylene Diaquo Complex
cis- [Pt2(n-C3H7NH2)2] (127 g, 0.22 mol) was slurried with a warm (500C) solution of silver nitrate (73 g, 0.43 mol) in 130 mls of water. The mixture was stirred for 4 hours during which time the yellow suspension turned dark grey. The mixture was then treated with charcoal, stirred and filtered through a porosity 4 sinter. The residue was triturated with water (20 mls) and the filtrates combined to give a clear orange solution (total volume 1 50 mls). The addition of a crystal of NaCI gave no precipitate of AgCl which indicated that the solution was silver-free.The solution was treated with charcoal and filtered through a porosity 4 sinter immediately before use as there was a tendency for the pale yellow solution to darken owing to slow decomposition to platinum.
Example 3:
Preparation of the n-Pentylamine Diaquo Complex
cis -[Ptl2 (n-c5HllNH2}2] (86 g, 0.14 mol) was slurried with a warm (500C) solution of silver nitrate (43.8 g, 0.27 mol) in 100 mls of water and 80 mls of ethanol. The mixture was stirred overnight, and then stirred with charcoal.
The solids were filtered off on a porosity 4 sinter to give a cloudy orange solution. This cloudiness
persisted despite several filtrations through porosity 4 sinters.
Example 4:
Cis-bis(chloroacetato) Bis(n-propylamine)platinum Il, cis-[P tCLCH2C02)21 n-C3H7NH2)2d - An aqueous solution of the n-propylamine diaquo complex (37 mls, 0.054 mol) was added to a
warm, stirred solution of potassium chloroacetate, prepared from chloroacetic acid (15 g, 0.16 mol) and potassium hydroxide (9 g, 0.16 mol) in 100 mls of water. A dark, oily solid formed which changed to a more brittle solid on standing (60 hours). The pale yellow brown solid was filtered off on a porosity 3 sinter, washed well with water and dried in vacuo at 500C.
Crude yield=14.3 g (54%)
The crude produce (14.3 g) was dissolved in 125 mls of boiling ethanol. The solution was stirred with charcoal, filtered while hot through a porosity 4 sinter and allowed to cool. A white crystalline solid was formed.
Yield=6.4 g (overall yield=24%).
Elemental analysis
Pt C H N O C/ Calculated % 39.0 24.0 4.4 5.6 12.8 14.2 Found % - 23.8 4.4 5.5 -
Example 5:
Cis-bis(bromoacetato)bis(n-propylamine)platinum(II), cis-[Pt( BrCH2CO2)2 (n-C3H7NH2)2]
Bromotacetic acid (5 g, 0.04 mol) was added to an aqueous solution of the n-propylamine diaquo
complex (26 ml, 0.01 mol). A concentrated aqueous solution of sodium hydroxide was then added to the stirred solution until the pH had increased to 67. This gave an oil which transformed to a solid on standing overnight. The solid was then filtered off on a porosity 3 sinter, washed well with water and dried by suction.
Crude yield=1.5 g (25%) The crude bromoacetato complex was rather inefficiently recrystallised from 5 ml of hot ethanol, which gave pale yellow crystals.
Yield=0.1 g (overall yield=2%)
Elemental Analysis
Pt C H N O Br Calculated % 33.1 20.4 3.8 4.8 10.9 27.1
Found % - 19.4 3.6 4.8 - - Infra-red Spectrum
The nitrogen-hydrogen stretching modes (i'N-H) occur at 31 90, 31 50 and 3110 cm-1 and there is a bromoacetate absorption at 1615 cm-1 (Pc=o) Example 6:
Cis-bis(n-butylamine) Bis(chloroacetato)platinum(ll),
cis - [Pt(ClCH2CO2)2( n-C4H9NH2 2]
A solution of potassium chloroacetate in 100 mls of water, prepared from chloroacetic acid (21.6 g, 0.14 mol) was added to a solution of the n-butylamine diaquo complex in water (76 mls, 0.046 mol).
A blue solution was formed immediately in which a dark blue-green oil settled. A white suspension was also observed. The mixture was allowed to stand for 60 hours and then the solids were filtered off on a porosity 3 sinter, washed well with water and air dried. The solid was then crushed in a mortar, washed with diethyl ether and dried in vacuo at 600C. The crude product was pale green.
Crude yield=11.1 g (42%)
The crude product (9.6 g) was dissolved in 50-60 mls of hot ethanol. The orange solution was stirred with charcoal and filtered while hot through a porosity 4 sinter. White acicular crystals formed on cooling the filtrate which was subsequently chilled at 50C overnight. The crystals filtered off on a porosity 3 sinter and washed twice with ethanol, causing them to effloresce to a white powder, which was dried in vacuo at 400C.
Yield-3.3 g (overall yield=12.6%) Elemental Analysis
Pt C H N O Cl
Calculated% 36.9 27.3 5.0 5.3 12.1 13.4
Found % - 26.9 5.0 5.3 -
Infra-red Spectrum
The nitrogen-hydrogen stretching modes (PN-H) occur at 3195 and 3130 cm-l and there is a chloroacetate absorption at 1650 cm-1 (vC=O).
Example 7:
Aquobis(n-butylamine)sulphatoplatinum(ll), [Pt(504) (H201 (n-C4H9NH2) lj Concentrated sulphuric acid (7 ml, 0.13 mol) was added to a chilled, stirred solution (42 ml) of the n-butylamine diaquo complex (0.024 mol). After storage at 50C for 3 days white crystals appeared.
which were filtered off on a porosity 3 sinter and washed with water. The crystals effioresced on washing to form a white powder, which was dried in vacuo at 500 C.
Crude yield=2.1 g (19%) The complex was insoluble in hot water, ethanol, aqueous sodium sulphate solution, methanol and acetone. However, the complex was soluble in concentrated sulphuric acid and was recrystallised as follows.
The crude sulphato complex (0.8 g) was dissolved in 1 ml of warm concentrated sulphuric acid on a porosity 4 sintered glass filter. The yellow solution so formed was then drawn through by suction into a receiver flask containing ice-cold water (2 ml). This gave a white precipitate-which was filtered off, washed with ethanol and dried in vacuo.
Yield=0.4 g (overall yield=9.5%)
Elemental Analysis
Pt C H N O S Calculated % 42.8 21.1 5.3 6.2 17.6 7.0 Found - 20.8 5.2 6.1 - - Infra-red Spectrum
The nitrogen-hydrogen stretching modes (VN~H) occur at 3220 and 3120 cm-1 and there are sulphate absorptions at 1170, 111 5, 1030 and 940 cm~'.
Example 8:
Bis(n-butylamine)oxalatoplatinum(II)
[Pt(C2O4)(i-C4H9NH2X2]
A solution of the n-butylamine diaquo complex (37 ml, 0.024 mol) was added to a warm stirred solution of potassium oxalate (13 g, monohydrate, 0,07 mol) in 40 ml of water. The white precipitate so formed was stirred for 30 minutes, filtered off on a porosity 4 sinter, washed with water and dried in vacuo at 500C.
Crude yield=5.4 g (50%)
The crude oxalto complex was recrystallised as follows. The product was added to a stirred, vigorously boiling aqueous solution of 0.1 M potassium oxalate (800 ml). The solution was boiled for
30 minutes to effect dissolution during which time the solution darkened owing to some platinum formation. The solution was then treated with charcoal, stirred, cooled to 80 C and filtered through a
porosity 4 sinter. White crystals formed on cooling the filtrate to 250C and after storage for 3 days at
50C, the product was filtered off, washed with water and air dried.
Yield 0.2 g (2%)
The low yield is due to instability of the product in boiling 0.1 M potassium oxalate.
Elemental Analysis
Pt C H N O Calculated % 45.4 28.0 5.2 6.5 14.9 Found - 27.2 5.1 6.3 - Infra-red Spectrum
The nitrogen-hydrogen stretching modes (vN=H) occur at 3200 and 3110 cm-1 and there are oxalate absorptions at 1695 and 1669 cm- due to the carbonyl stretching vibration (vC=O). The spectra of the crude iso- and n-butylamine oxalato complexes showed strong peaks at 775 and 1300 cm-1. These peaks were absent from the spectra of the recrystallised compounds.
Example 9:
Oxalatobis(n-propylamine)platinum(ll)
[Pt(C2O4) (n-C3H7NH2)2]
A warm saturated aqueous solution of potassium oxalate (38 g, monohydrate, 0.20 mol) was added to a solution of the n-propylamine diaquo complex (120 g, 0.04 mol). The white precipitate so obtained was stirred for 1 hour at 50 C, filtered off on a porosity 3 sinter, washed with water and dried in vacuo.
Crude yield=10.8 g (67%)
The crude product (5.8 g) was dissolved in a vigorously boiling solution of K2C204 H2O (13 g, 0.07 mol) in 700 mls of water. The clear pale yellow solution formed was treated with charcoal, stirred, cooled to 800C, filtered through a porosity 4 sinter and allowed to cool to 25 C during which time
crystallisation occurred. The mixture was chilled at 5 C overnight and the crystals were filtered off on a porosity 3 sinter, washed with water and dried in vacuo.
Yield=48% (based on crude produce).
Elemental analysis
Pt C H N O
Calculated % 48.6 23.9 4.5 7.0 16.0
Found % - 23.5 4.5 6.8
Infra-red Spectrum
The nitrogen-hydrogen stretching modes (VN~H) occur at 3250 and 31 50 cm-1 and there are oxalate absorptions at 1 695, 1 680 and 1655 cm-1 due to the carbonyl stretching vibrations (vC=O).
Example 10:
Cis-aquabis(n-butylamine)sulphato Platinum(ll) cisfPt(sI(H;C)(n-c4NH2l2 Concentrated sulphuric acid (26 ml, 0.49 mole) was added dropwise to a stirred aqueous solution of n-butylamine diaquo complex (43 ml, 0.049 mole) after cooling to 5 C. The solution, after storing overnight at room temperature, deposited a white precipitate, which was filtered off on a porosity 3 sinter, washed successively with a small amount of cold water and ethanol and dried in vacuo at 60 C.
Yield of crude product=3 g.
Assay:
Pt C H N O S
Calculated% 42.8 21.1 5.3 6.2 17.6 7.0 Found - 21.0 5.0 6.5 - - Infra-red spectrum:
The VN~H modes occur at 3210 and 3140 cm-1, sulphate absorbs at 1127 and 1106, 1021 and 936 cm-1, and water absorptions occur at 1609 and 3500 cm-1.
Example 11:
Preparation of Cis-aquabis(n-propylamine)sulphato Platinum(ll)
cis-[Pt(SO4) (H2O)(n-C3H7NH2)2]
The n-propylamine diaquo complex (0.068 mole, assuming 100% conversion) was cooled to 50C and concentrated sulphuric acid (37 ml, 0.68 mole) was added dropwise so that the temperature of the solution did not rise above 20 C. After addition of H2SO4 was complete the solution was stirred for an hour during which time a small amount (0.5 g) of a white solid precipitated. After filtration the filtrate was allowed to stand for 5 days and some white needles separated. These were filtered off on a porosity 3 sinter, washed with ice cold water and ethanol and dried in vacuo at 800C.
Yield=4.6 g (15%) Assay:
Pt C H N O S
Calculated % 45.64 16.86 4.72 6.55 18.72 7.50 Found% - 17.12 4.19 6.16 - - Infra-red spectrum: L'N-H occurs at 3220 at 3130 cm-1, sulphate absorptions are found at 1230, 1110, 1010 and 993 cm-1, water absorptions occur at 1 595 and 3500 cm-1.
Example 12:
Oxalatobis(n-petylamine)platinum(II) [Pt tC2O4) (n-C5H11NH2)2] A solution of the n-petylamine diaquo complex (45 mls, 0.035 mol) in aqueous ethanol was added to a solution of K2C204. H20 (32 g, 0.17 mol) in 100 mls of water, to form a fine white precipitate after 5-1 0 seconds. The mixture was stirred for 30 minutes and the product filtered off on a porosity 3 winter, washed well with hot water and dried in vacuo at 600C.
Crude yield=5.8 g (36%)
The complex was recrystallised from hot ethanol without apparent decomposition i.e. the crude product (2.8 g) was dissolved in approx. 1 50 mls of boiling ethanol. The solution was concentrated to a volume of 30-40 mls, treated with charcoal and filtered through a porosity 4 sinter. A white solid formed when the solution was cool. This was filtered off on a porosity 3 sinter. More white solid was obtained when an equal volume of water was added to the ethanolic filtrate. The purified products were combined, washed with water, ethanol and dried in vacuo.
Yield=1.7 g (overall yield=22%) Elemental Analysis
Pt(C2O4)(n-C5HHNH2)]
Pt C H N O
Calculated% 42.7 31.5 5.6 6.2 14.0 Found - 31.8 5.6 6.2 - Infra-red spectrum
The nitrogen-hydrogen stretching modes (VN~H) occur at 3200 and 3110 cm- and there are oxalate absorption at 1693 and 1667 cm-1 due to the carbonyl stretching vibration (vC=O).
Example 13:
Cis-bis(chloroacetato) Bis(n-pentylamine)platinum(Il).
cis-[Pt(clcH2c02)2l n-CSHllNH212j
A solution of potassium chloroacetate, prepared from chloroacetic acid (19.7 g, 0.21 moll and potassium hydroxide (11.8 g, 0.21 mol) in 100 mls of water, was added to a solution of the n pentylamine diaquo complex (0.07 mol) in aqueous ethanol (90 mls) at 250C. This gave a brown oil.
The mixture was stirred for 30 minutes and allowed to stand for 60 hours during which time the oil hardened to a brown solid. The solid was filtered off on a porosity 3 sinter, washed well with water, air dried, washed with diethyl ether and then dried in vacuo at 600C.
Crude yield=14.0 g (36%)
The crude product (8 g) was added to 30 mls of boiling ethanol. The brown solution was stirred with charcoal, filtered hot through a porosity 4 sinter and allowed to cool. This gave a white solid which was filtered off through a porosity 3 sinter, and washed with ethanol.
Yield=4.8 g (overall yield=22%) Elemental analysis
Pt C H N O Cl Calculated% 35.1 30.2 5.4 5.0 11.5 12.7
Found % - 29.9 5.5 5.0 -
Infra-red spectrum
The nitrogen-hydrogen stretching modes (VN~H) occur at 3200, 3160 and 31 10 cm-1 and there are chloroacetate absorptions at 1600 cm-t owing to the carbonyl stretching vibrations.
Example 14: cis-[ctz(n-c3H7NH Concentrated hydrochloric acid (50 ml.) was added to a solution of the n-propylamine diaquo complex and stirred at 400C for two hours. The slurry of crude product was cooled overnight, filtered and the residue washed with water ethanol and dried in vacuo. The crude product was recrystallised from NN dimethylformamide (500 ml) by addition of 1 litre of 0.1 N hydrochloric acid.
Yield: 36.7 g, 80% (based on 64 g [Ptí2A2]) IR v Pt-Cl 320 cm-'
Example 15: cis-[Ptct2(nNH2)2] This complex was prepared in an identical manner to that described in Example 14.
Yield=62% Example 16: Cis-dichlorobis( 1 -aminopentane)platinum(ll) n-amylamine (0.70 g; 8 m.mol) was added to a solution of K2PtCI4 (1.66 g; 4 m.mol) in water (1 5 ml) and sufficient methanol (5 ml) was added in order to produce a homogeneous solution. The reaction mixture was left overnight and the pale yellow solid that separated was filtered off, and washed successively with hot, 6 M hydrochloric acid, water, acetone, methanol, and ether.
Analysis:
C H N
Calculated % 27.3 5.95 6.4
Found % 27.0 5.80 6.3
The following complexes were prepared in a similar way: cis-dichlorobis( 1 -aminohexane)platinum(ll) cis-dichlorobis( 1 -aminoheptane)platinum(ll)
cis-dichlorobis(2-aminoheptane)platinum(ll)
cis-dichlorobis( 1 -aminooctane)platinum(ll)
Clinical Testing Data
Complexes according to the invention were tested for antitumour activity against L-1 210 leukaemia, ADJ/PC6A tumour or S1 80 solid tumour in mice. In the results which follow, dosages are quoted in mg/Kg body weight and the evaluation of effectiveness (% T/C) against L12 10 is calculated as the median survival time of treated mice divided by the median survival time of untreated (control) mice expressed as a percentage.Thus a % TIC of 100 indicates no activity and a % T/C of greater than or equal to 125 is considered to be indicative of significant antitumour activity.
Against a solid tumour, the % TIC is a measure of tumour regression and is the percentage of tumour weight in treated mice to that in control mice. Against ADJ/PC6A and S180, several dose levels were given and ranged from lethal to non-tumour inhibitory, allowing the calculation of LD50 and
ID80 (minimum dose to cause 90% tumour inhibition) in one experiment. The ratio LDsO/íDgO is the therapeutic index and is a measure of the selectivity of the compound as an anti-tumour agent. All compounds were administered intraperitoneally as a single dose suspended in arachis oil.
Bis(n-propylamino)bis(chloroacetato)platinum(II)
L1210 Single dose (i 12 mg/Kg % T/C=1 67 (Z 24 mg/Kg % T/C=167 Daily dose for 9 days @ 6 mg/Kg % T/C= 225
Bis-(n-propylamino)oxaltoplatinum(ll) L1210 Single dose # 59 mg/Kg%T/C=129 Daily dose for 9 days 1 5 mg/Kg- /Q T/C=143 Ga 30 mg/Kg % T/C=143
Bis-(n-butylamine)-bis-(chloroacetato)platinum(ll)
L1210 Single dose (Z 256 mg/Kg % T/C=107
Daily Dose for 9 days (b 32 mg/Kg % T/C=1 36 Bis-(ethylamine)oxaltoplatinum(ll) ADJ/PC6A I D90=3 .9 LDso=38 TI=9.7
S1 80 (carrier water) T/C=2 1% @ 10 mg/Kg Cis-bis(n-propylamine)dichloroplatinum(ll)
ADJ/PC5A ID so= < 12 LD50=26.5 TI= > 2.2 L1 210 Single dose Gw 8 mg/Kg %T/C=1 57 Daily dose for 9 days @ 4 mg/Kg % T/C=1 57
Cis-bis-(n-butylamine)dichloroplatinum(ll)
ADJ/PC6A íDgO= < 10 LD50=1 10TI= > 1 1 Cis-bis-(n-pentylamine)dichloroplatinum(ll)
ADJ/PC6A LD90=37 LD50=92 TI=2.5
Claims (13)
1. A composition of matter comprising a cis coordination compound of platinum having the structure
in which X and Y are the same or different ligands selected from halide sulphate, phosphate, nitrate, carboxylate, substituted carboxylate and water and A and B are the same or different straight-chain amines coordinated to the Pt through their N atoms, such that the platinum is present as Pt2+.
2. A composition according to Claim 1 wherein the phosphate is in the form of H2PO4- or HP042-.
3. A composition according to Claim 1 or Claim 2 wherein X and/or Y is represented by carboxylate or substituted carboxylate having the general formula CnR2n+1 CO2H, where n is an integer from 1 to 9 inclusive and that the R groups are the same or different and are selected from hydrogen, substituted or unsubstituted straight- or branched-chain alkyl, aryl, alkaryl, aralkyl, alkenyl, cycloalkyl and cycloalkenyl, halogen, pseudohalogen, hydroxy, carbonyl, formyl, nitro, amido, amino, alkoxy, aryloxy, and sulphonic acid salts.
4. A composition according to Claim 3 where the R group includes oxygen and sulphur that one double-bonded oxygen or sulphur atom is represented by two R groups.
5. A composition according to Claim 1 wherein X and Y are carboxylate.
6. A composition according to Claim 5 wherein X and Y together comprise a dicarboxylate bidendate ligand having the general formula: OOC ~(CRY IRZ2)n l-COO- wherein N1 is an integer from 2 to 6, R1 and R2 are the same or different and are selected from H, lower alkyl, aryl, alkaryl, aralkyl, alkenyl, cycloalkyl, cycloalkenyl, alkoxy, aryloxy, halogen, pseudohalogen,
OH, or are combined with the carbon atoms to form a cycloalkyl or an aryl group, and substituted derivatives thereof, and y and z are either 0 or 1 as long as (y+z) is equal to 1 or 2.
7. A composition according to Claim 6 wherein the dicarboxylate ligand is selected from the group consisting of substituted or unsubstituted succinato, glutarato (pentanedioato), adipato(hexamedioato), pemelato (heptanedioato), malato (cis-butenedioato) and phthalato) (obenzenedicarboxylate) ligands.
8. A composition according to Claim 7 wherein the dicarboxylate ligand includes a substituent selected from the group consisting of lower alkyl, (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl); aryl, (e.g. phenyl, lower alkyl-, lower alkenyl-, halo-, nitro-, lower alkoxy-substituted phenyl and naphthyl); aralkyl, (e.g. phenylmethyl (benzyl), 2-1 (naphtyl methyl); alkenyl, (e.g. 4-amino-l-butene, allyl); cycloalkyl, (e.g. cyclopropyl, cyclohexyl); cyclo-alkenyl, (e.g. 2-cyclo-penten- 1 -yl), 2-cyclohexen- 1 -yl); alkoxy; (e.g. methoxy, ethoxy), and hydroxy.
9. A composition according to Claim 1 wherein the straight-chain amine has the general formula n-CxR32x +INH2 in which x is an integer from 1 to 9 inclusive and the R3 groups are the same or different and are selected from hydrogen, aryl, cycloalkyl and cycloalkenyl, aralkyl, halogen, pseudohalogen) as hereinafter defined) hydroxy, alkoxy, aryloxy, carbonyl, formyl, nitro, amido, amino, acylamino, sulphonic acid, sulphonic acid salt, carboxylic acid ester and carboxylic acid salt.
1 0. A composition according to Claim 9 wherein all R3 groups are hydrogen.
ii. A composition according to Claim 9 wherein at least one R3 group is not hydrogen.
12. A composition according to Claim ii wherein the said at least one R3 group is selected from the group consisting of sulphonic acid, carboxylic acid, a sulphonic acid salt and a carboxylic acid salt.
13. A composition according to any one of Claims 10 to 12, wherein R3 includes oxygen and sulphur such that a doubly-bonded oxygen or sulphur atom is represented by two R3 groups.
1 4. A composition of matter according to Claim 1 and as described in any one of the Examples.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB7841111A GB2025938B (en) | 1977-10-19 | 1978-10-18 | (ii)-amine complexes |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB4349177 | 1977-10-19 | ||
GB7841111A GB2025938B (en) | 1977-10-19 | 1978-10-18 | (ii)-amine complexes |
Publications (2)
Publication Number | Publication Date |
---|---|
GB2025938A true GB2025938A (en) | 1980-01-30 |
GB2025938B GB2025938B (en) | 1982-11-03 |
Family
ID=26265167
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB7841111A Expired GB2025938B (en) | 1977-10-19 | 1978-10-18 | (ii)-amine complexes |
Country Status (1)
Country | Link |
---|---|
GB (1) | GB2025938B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2140804A (en) * | 1983-06-01 | 1984-12-05 | Shionogi & Co | Glycolic acid type platinum complexes |
-
1978
- 1978-10-18 GB GB7841111A patent/GB2025938B/en not_active Expired
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2140804A (en) * | 1983-06-01 | 1984-12-05 | Shionogi & Co | Glycolic acid type platinum complexes |
Also Published As
Publication number | Publication date |
---|---|
GB2025938B (en) | 1982-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4225529A (en) | Compositions containing platinum | |
CA1164882A (en) | Compositions containing platinum | |
CA1117545A (en) | Compositions containing platinum | |
US4115418A (en) | 1,2-diaminocyclohexane platinum (ii) complexes having antineoplastic activity | |
US4230631A (en) | Platinum coordination compounds | |
US4256652A (en) | Platinum complex | |
US4119653A (en) | Co-ordination compounds of platinum | |
US4284579A (en) | (N-Phosphonacetyl-L-aspartato)(1,2-diaminocyclchexane)platinum(II) or alkali metal salt | |
EP0166366B1 (en) | Novel platinum complexes | |
KR970010594B1 (en) | Platinum complexes of malonic acid derivatives and process for the preparation thereof | |
US5107007A (en) | Bis-platinum complexes as chemotherapeutic agents | |
HU184922B (en) | Process for preparing platinum/iv./-diamine complexes and pharma ceutical compositions containing thereof | |
CA1134378A (en) | Cis-platinum(ii) amine lactate complexes | |
US4614811A (en) | Novel organoplatinum(II) complexes and method for the preparation thereof | |
US4234500A (en) | Ethylenediamine platinum(II) and 1,2-diamino-cyclohexane platinum(II) pyrophosphate complexes | |
US4687780A (en) | Anti-tumor compounds of platinum | |
US4182724A (en) | Compositions containing platinum | |
GB2025938A (en) | Pt(II)-amine Complexes | |
US4457926A (en) | Cis-Platinum(II) amine ascorbate complexes | |
US4175133A (en) | 1,2-Diaminocyclohexane platinum (II) complexes having antineoplastic activity against L1210 leukemia | |
US5770591A (en) | Bis-platinum complexes as chemotherapeutic agents | |
KR890004351B1 (en) | Process for the preparation of anti-tumor platinum complexs | |
CA1097670A (en) | Compositions containing platinum | |
EP0308910A2 (en) | Novel platinum complex | |
Hill et al. | Synthesis, characterization and anti-tumour testing of some platinum (II) amine complexes containing 1, 1-and 1, 2-cyclobutanedicarboxylate ligands |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PCNP | Patent ceased through non-payment of renewal fee |
Effective date: 19951018 |